Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
Kyungae NamDaniel Sung-Ho ChoHyunji KimByungjin KwonYebin YoonChanhyun ParkEui-Soon KimJong-Chan YounSun-Kyeong ParkPublished in: Clinical drug investigation (2023)
Most of the studies reported the cost-effectiveness of dapagliflozin and empagliflozin in patients with HFrEF. However, the cost-effectiveness of empagliflozin differed from country to country regarding patients with HFpEF. We suggest that further economic evaluation of SGLT2 inhibitors should focus on patients with HFpEF in more countries.